Empagliflozin

Empagliflozin belongs to the gliflozin family of SGLT2 inhibitors, drugs that lower blood sugar by blocking the reabsorption of glucose in the kidney. Chemically it is a C-glucoside derivative. It was developed by Boehringer Ingelheim together with Eli Lilly and was first approved for type 2 diabetes in the mid-2010s.

Beyond glucose control, empagliflozin turned out to have striking cardiovascular benefits. The EMPA-REG OUTCOME trial, in people with type 2 diabetes and established cardiovascular disease, found that empagliflozin reduced the combined risk of cardiovascular death, heart attack, and stroke, and notably lowered death from cardiovascular causes and hospitalization for heart failure compared with placebo ^[1]. These results reframed the drug as a cardioprotective agent rather than merely a glucose-lowering one.

Later trials extended its use to people without diabetes. In EMPEROR-Reduced, empagliflozin reduced cardiovascular death and heart-failure hospitalization in patients with heart failure and a reduced ejection fraction, whether or not they had diabetes ^[2], and companion research showed benefit in heart failure with preserved ejection fraction. The EMPA-KIDNEY trial then demonstrated that empagliflozin slowed the progression of chronic kidney disease and lowered the risk of cardiovascular death across a broad range of patients ^[3].

Empagliflozin is now approved for type 2 diabetes, heart failure, and chronic kidney disease. Because it raises the amount of glucose in the urine, characteristic side effects include genital yeast infections and urinary tract infections and, uncommonly, a form of diabetic ketoacidosis that can occur even when blood sugar is only modestly elevated. It is taken as a once-daily oral tablet, alone or combined with metformin or other agents ^[1][2][3].

Empagliflozin is an SGLT2 inhibitor and commonly causes genital yeast and urinary tract infections and increased urination, and it can produce volume depletion and low blood pressure. Less common but serious risks include euglycemic diabetic ketoacidosis (which can occur with near-normal glucose), rare necrotizing perineal infection (Fournier's gangrene), and hypoglycemia when used with insulin or sulfonylureas. Adequate hydration and awareness of ketoacidosis symptoms are important, especially around illness, fasting, or surgery.

Empagliflozin, an SGLT2 inhibitor, interacts with drugs that modulate organic anion transporters and breast cancer resistance protein. Telmisartan, an angiotensin receptor blocker, increases empagliflozin plasma exposure (AUC and Cmax) through inhibition of BCRP and organic anion transporting polypeptide transporters ^[23]; this is a pharmacokinetic transporter-mediated interaction where telmisartan reduces empagliflozin's renal and hepatic clearance. The effect is directional; telmisartan changes empagliflozin levels more than empagliflozin affects telmisartan. Dorzagliatin, a glucokinase activator, shows no clinically significant pharmacokinetic interaction with empagliflozin despite both being transporter substrates ^[24]. Interactions with other BCRP inhibitors (such as certain antiretrovirals or cyclosporine) have not been systematically studied in humans.

Checking a whole stack? Run it through interactions + stacks.

Empagliflozin was developed jointly by Boehringer Ingelheim and Eli Lilly and Company as a selective inhibitor of the sodium-glucose cotransporter-2 (SGLT2), a protein in the kidney that reclaims filtered glucose back into the blood. It received United States approval in 2014 under the brand name Jardiance for the treatment of type 2 diabetes. Its profile was transformed in 2015 when the EMPA-REG OUTCOME trial reported that the drug reduced cardiovascular death in people with type 2 diabetes and established cardiovascular disease, the first time a glucose-lowering agent had shown such a benefit and a finding that reoriented the entire field toward cardiovascular and renal protection.

Subsequent landmark trials broadened its reach far beyond diabetes: the EMPEROR program demonstrated benefit in heart failure across the spectrum of ejection fraction, and the EMPA-KIDNEY trial showed slowing of chronic kidney disease progression. On the strength of this evidence its approved uses now encompass type 2 diabetes, heart failure, and chronic kidney disease.

Empagliflozin is widely viewed as one of the most consequential cardiometabolic medicines of the past decade, a drug that began as a diabetes treatment and became a cornerstone therapy for heart failure and chronic kidney disease in patients with and without diabetes. Its clinical trial record is unusually deep and consistent, with large randomized studies showing reductions in cardiovascular death, heart-failure hospitalizations, and the progression of kidney disease.

Physicians value that it is taken once daily by mouth and carries a low risk of causing hypoglycemia on its own, since its glucose-lowering action depends on filtered glucose rather than on driving insulin. The honest cautions include an increased risk of genital fungal infections, volume depletion, and the rare but serious possibility of euglycemic diabetic ketoacidosis. Weighed against its documented protection of the heart and kidneys, it stands as a genuinely landmark therapy.